ArticleNature communications2024
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- JN.1-adapted vaccination is associated with readjustment of ancestral memory B cells toward neutralization within the JN.1 antigenic space.Nature communications · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Exploring the diverse binding ability of SARS-CoV-2 variant RBDs to different antibody classes: a computational study.RSC advances · 2026Article
- Engineered IgA-Fc fusion protein with bioactive nanobody neutralizes SARS-CoV-2 variants with mucosal delivery potential.The Journal of biological chemistry · 2026Article
- Article
- Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches.Emerging microbes & infections · 2025Article
- Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Vaxtherapy, a Multiphase Therapeutic Protocol Approach for Longvax, the COVID-19 Vaccine-Induced Disease: Spike Persistence as the Core Culprit and Its Downstream Effects.Diseases (Basel, Switzerland) · 2025Article
- Plant-produced SARS-CoV-2 antibody engineered towards enhanced potency and in vivo efficacy.Plant biotechnology journal · 2025Article
- Structural Immunology of SARS-CoV-2.Immunological reviews · 2025Review
- Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.Influenza and other respiratory viruses · 2025Review
- Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.iScience · 2024Article
- Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.Viruses · 2024Review
- Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.Npj viruses · 2024Article
- A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.Frontiers in immunology · 2024Article
- Application of the humanized mouse model in research into SARS-CoV-2 infection (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Leire de Campos-Mata *Translational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
Benjamin Trinité *IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.ORCID 0000-0003-3809-042X
Andrea Modrego *Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Sonia Tejedor VaqueroTranslational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.ORCID 0000-0003-2873-4981
Edwards PradenasIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.ORCID 0000-0001-5162-8920
Anna Pons-GrífolsIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.ORCID 0000-0002-8402-3941
Natalia Rodrigo MeleroCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Diego CarleroCentro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Silvia MarfilIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
César SantiagoCentro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.ORCID 0000-0002-5149-1722
Dàlia Raïch-ReguéIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.ORCID 0000-0001-7656-5700
María Teresa Bueno-CarrascoCentro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.ORCID 0000-0003-1586-2589
Ferran Tarrés-FreixasIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Ferran AbancóIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Victor UrreaIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.ORCID 0000-0002-2577-856X
Nuria Izquierdo-UserosIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.ORCID 0000-0002-1039-1821
Eva Riveira-MuñozIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Ester BallanaIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Mónica PérezUnitat Mixta d'Investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Júlia Vergara-AlertUnitat Mixta d'Investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Joaquim SegalésUnitat Mixta d'Investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.ORCID 0000-0002-1539-7261
Carlo CarolisCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain. carlo.carolis@crg.eu.ORCID 0000-0003-4240-1139
Rocío ArranzCentro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain. rarranz@cnb.csic.es.ORCID 0000-0001-5321-0915
Julià BlancoIrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain. jblanco@irsicaixa.es.ORCID 0000-0002-2225-0217
Giuliana MagriTranslational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain. gmagri@imim.es.ORCID 0000-0002-0163-3542
Funding
Government of Catalonia | Departament de Salut, Generalitat de Catalunya COVID19 CallMinistry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) MS19/00002
Abstract
Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived from a receptor binding domain (RBD)-specific IgA
Indexed as
Antibodies, MonoclonalCOVID-19AnimalsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralCryoelectron MicroscopyHumansMiceSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.